Filing Flows › Coherus Oncology (CHRS) › Q3 2026
Coherus Oncology (CHRS) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 9, 2026
Coherus Oncology (CHRS) reported revenue of $14.3M for the third quarter 2026 (Q3 2026), +23% from a year earlier and -0.2% from the quarter before. Operating margin was -235.7%, net loss $39.3M (275.6% of revenue).
Coherus Oncology, Q3 2026: revenue $14.3M (+23% year over year), operating margin -235.7%, net loss $39.3M, operating cash flow −$34.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.3M | -0.2% | +23% |
| Operating profit | −$33.6M | — | — |
| Net earnings | −$39.3M | — | — |
| Operating cash flow | −$34.0M | — | — |
What changed
Revenue was $14.3M in Q3 2026, up 23% year over year and roughly flat from the previous quarter. Toripalimab was the largest line at 98% of revenue. Toripalimab added $2.8M year over year (up 25%), 105% of the total change. Other revenue declined 34%.
Operating costs exceeded revenue by $33.6M, an operating margin of -235.7%. Total costs fell 14% while revenue rose 23%. The quarter ended with a net loss of $39.3M, wider than the previous quarter's $20.6M loss.
Operating cash flow was −$34.0M. Non-cash charges added back $853K of depreciation and amortization and $3.7M of share-based compensation.
Questions
What was Coherus Oncology's revenue in the third quarter 2026?
Coherus Oncology (CHRS) reported revenue of $14.3M for the third quarter 2026 (Q3 2026), +23% from a year earlier and -0.2% from the quarter before.
Was Coherus Oncology profitable in the third quarter 2026?
Operating loss was $33.6M (-235.7% of revenue) and net loss $39.3M.
Source: Coherus Oncology 10-Q on SEC EDGAR.